RedHill Biopharma releases corporate presentation outlining Talicia commercialization, late-stage pipeline progress

Pipeline priorities include opaganib in a Phase 2 combination study with Bayer’s darolutamide in prostate cancer, backed by multiple late-stage programs.

Talicia is positioned as the leading branded H. pylori prescription among U.S. gastroenterologists. The product has U.S. patent protection through 2042 and QIDP exclusivity through 2027.

RedHill Biopharma outlined its U.S. specialty pharma strategy focused on GI diseases, infectious diseases, oncology, led by Talicia commercialization.

• FY 2025 net revenue: USD 7.8 million
• Cash balance: USD 4.1 million
• Gross margin: 74.6%
• Equity financing capacity: USD 31.7 million via an at-the-market purchase agreement, backed by a SEPA facility